| Diabetes Mellitus, Non-Insulin-Dependent
Glyxambi vs Janumet
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Glyxambi vs Janumet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJanumet has a higher rate of injection site reactions vs Glyxambi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Janumet but not Glyxambi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Glyxambi
Janumet
At A Glance
Oral
Daily
SGLT2 inhibitor / DPP-4 inhibitor
Oral
Twice daily
DPP-4 inhibitor / biguanide combination
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases 10 mg empagliflozin/5 mg linagliptin once daily in the morning, with or without food; may increase to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control; not recommended with eGFR less than 30 mL/min/1.73 m2; withhold at least 3 days prior to surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent 50 mg sitagliptin/500 mg metformin HCl twice daily with meals as starting dose for patients not on metformin; for patients on metformin HCl 850 mg twice daily, start at 50 mg sitagliptin/1000 mg metformin HCl twice daily; max 100 mg sitagliptin/2000 mg metformin HCl daily; do not split or divide tablets.
Contraindications
- Hypersensitivity to empagliflozin, linagliptin, or any excipient in GLYXAMBI (including anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of a serious hypersensitivity reaction to JANUMET, sitagliptin, or metformin, such as anaphylaxis or angioedema
Adverse Reactions
Most common (>=5%) Urinary tract infection, nasopharyngitis, upper respiratory tract infection
Serious Diabetic ketoacidosis, pancreatitis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, genital mycotic infections, hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, constipation, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria
Most common (>=5%) Diarrhea, upper respiratory tract infection, headache, nasopharyngitis, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia
Serious Lactic acidosis, pancreatitis, heart failure, acute renal failure, hypoglycemia (with sulfonylurea or insulin), hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, hepatic enzyme elevations, fatal and non-fatal hemorrhagic and necrotizing pancreatitis, worsening renal function, acute renal failure, tubulointerstitial nephritis, rhabdomyolysis, constipation, myalgia, back pain, pruritus, mouth ulceration, cholestatic and hepatocellular liver injury
Pharmacology
Empagliflozin is a SGLT2 inhibitor that reduces renal glucose reabsorption by inhibiting the predominant transporter responsible for filtered glucose reabsorption, thereby increasing urinary glucose excretion; linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels.
Sitagliptin is a DPP-4 inhibitor that slows inactivation of incretin hormones GLP-1 and GIP, increasing insulin release and decreasing glucagon in a glucose-dependent manner; metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity by increasing glucose uptake and utilization.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Glyxambi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
Janumet
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Glyxambi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (6/8)
Janumet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Glyxambi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Janumet
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Glyxambi.
No savings programs available for Janumet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GlyxambiView full Glyxambi profile
JanumetView full Janumet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.